-

DeciBio Consulting adds Miguel Edwards, Ph.D., as a Partner and Head of its Bay Area Office

LOS ANGELES--(BUSINESS WIRE)--DeciBio Consulting, LLC, a precision medicine-focused strategy consulting and market intelligence firm, has tapped Miguel Edwards, Ph.D., as Partner.

At DeciBio, Miguel has emerged as an expert in tools and technologies such as next generation sequencing (NGS), single cell, liquid biopsies, NIPT, and multiomics. He leads engagements that conduct global primary and secondary research, evaluate product specifications, characterize competitive landscapes, and identify industry trends to determine potential strategic approaches.

He also serves as Managing Director of DeciBio’s Bay Area office and is a founding member of DeciBio Ventures.

“We are excited and proud to invite Miguel to join the partnership. He brings tremendous technical and strategic insights to our consulting clients and brings grit, mentorship, and humor to our team and the Bay Area office. We look forward to this next chapter in the firm and the new opportunities to accelerate innovation in precision medicine,” says Co-Founder David Cavanaugh.

“Miguel has built a reputation as an insightful thought partner with our clients, and we’re looking forward to having him lead and grow our firm. His expertise and perspectives in omics technologies and their role in precision medicine is unique and unmatched in the industry. Miguel also empowers and energizes our employees in ways that are invaluable to our organization. We are ecstatic to have him join the partnership,” stated DeciBio’s Co-Founder, Stephane Budel.

“DeciBio has been a fantastic place to build my career and expertise alongside like-minded individuals who are truly passionate about the life sciences and precision medicine. The content continues to be fulfilling and the relationships built with team members and clients are rewarding. I’m excited to enter the partnership and to continue to leverage my expertise for the benefit of our clients, our team members’ career trajectories, and our Bay Area expansion,” added Miguel Edwards, Ph.D.

Miguel earned a Ph.D. in Molecular Biology from UCLA and a B.A. in Biological Sciences from Hunter College - CUNY.

About DeciBio

DeciBio Consulting (www.decibio.com) is the leading strategy consulting, market intelligence, and SaaS firm dedicated to accelerating the adoption and impact of technologies enabling precision medicine.

Headquartered in Los Angeles, California, DeciBio serves a global base of clients and customers, ranging from startups to Fortune 500 healthcare corporations. DeciBio offers advisory services for growth planning, market and opportunity assessment, product and portfolio strategy, voice-of-customer feedback, technology assessment, and commercial due diligence.

Contacts

Kimberly Stacey
Info@DeciBio.com
310.451.4510

More News From DeciBio Consulting, LLC

Worldwide In Vitro Diagnostics (IVD) Market Forecasted to Grow at 4% p.a., Reaching $109B by 2030 – Market Report by DeciBio Consulting LLC

LOS ANGELES--(BUSINESS WIRE)--According to a comprehensive market report authored by DeciBio Consulting LLC, “In Vitro Diagnostic (IVD) Market Report 2025-2030”, the global in vitro diagnostics market is predicted to reach $109B by 2030. This growth will be driven by increasing access to and adoption of diagnostics, the development of new therapies requiring ongoing testing, and the rise of emerging technologies (e.g., computational pathology, liquid biopsy) poised to gain clinical traction and...

Proteomics Tools Market Forecast to Grow at ~4% p.a., Reaching ~$39B by 2030 – Market Report by DeciBio Consulting LLC

LOS ANGELES--(BUSINESS WIRE)--DeciBio Consulting LLC, a leading market intelligence and strategy consulting firm, announced the publication of its first edition, “Proteomics Tools Report: Research and Clinical markets (2025-2030).” This comprehensive report forecasts the global proteomics tools market to reach approximately $39 billion by 2030, growing at a compound annual growth rate (CAGR) of ~4% from an estimated $32 billion in 2025. DeciBio’s Proteomics Tools Market Report offers an in-dept...

Pharma R&D Services Market Forecast to Grow at 5% p.a., Reaching ~$129B by 2029 – Market Report by DeciBio Consulting LLC

LOS ANGELES--(BUSINESS WIRE)--DeciBio Consulting LLC, a leading market intelligence and strategy consulting firm, announced the publication of its first edition, “Pharma R&D Services Market Report (2024-2029).” This comprehensive report forecasts the global pharma R&D services market to reach approximately $129 billion by 2029, growing at a compound annual growth rate (CAGR) of 5% from an estimated $101 billion in 2024. DeciBio’s Pharma R&D Services Market Report offers an in-depth...
Back to Newsroom